Serological Responses to an Avian Influenza A/H7N9 Vaccine Mixed at the Point-of-Use With MF59 Adjuvant

Abstract

for the DMID 13-0032 H7N9 Vaccine Study Group IMPORTANCE Human infections with avian influenza A/H7N9 have resulted in high morbidity and mortality in China.OBJECTIVE To compare safety and immunogenicity of different doses of influenza A/Shanghai/2/13 (H7N9) vaccine mixed with or without the MF59 adjuvant. DESIGN, SETTING, AND PARTICIPANTS Multicenter, randomized, double-blind, phase 2 trial at 4 US sites enrolled 700 adults aged 19 to 64 years beginning in September 2013; 6-month follow-up was completed in May 2014.INTERVENTIONS The H7N9 inactivated virus vaccine was administered intramuscularly on days 0 and 21 at nominal doses of 3.75, 7.5, 15, or 45 μg of hemagglutinin (actual doses approximately 50% higher) with or without the MF59 adjuvant. A total 99, 100, or 101 participants were randomized to each group (7 groups; N = 700). MAIN OUTCOMES AND MEASURESProportions achieving day 42 antibody titer of 40 or greater or seroconversion (a minimum 4-fold increase to titer Ն40) with the hemagglutination inhibition assay; vaccine-related serious adverse events through month 13; and solicited postvaccination symptoms through day 7.RESULTS Hemagglutination inhibition antibodies were minimal after participants received an unadjuvanted vaccine. After receiving 2 doses of H7N9 vaccine at a dosage of 3.75 μg plus the MF59 adjuvant, day 42 seroconversion occurred in 58 participants (59%; 95% CI, 48%-68%). The peak seroconversion occurred at day 29 in 62 participants (62%; 95% CI, 52%-72%). The day 42 geometric mean titer was 33.0 (95% CI, 24.7-44.1). Higher antigen doses were not associated with increased response. For the neutralizing antibody assays, after receiving 3.75 μg of H7N9 vaccine plus the MF59 adjuvant, day 42 seroconversion occurred in 81 participants (82%; 95% CI, 73%-89%). The day 42 geometric mean titer was 81.4 (95% CI, 66.6-99.5). There was no statistically significant difference in day 42 hemagglutination inhibition seroconversion after mixing adjuvant with either the first or both 15 μg doses (n = 34 [35%; 95% CI, 25%-45%] vs n = 47 [47%; 95% CI, 37%-58%], respectively; P = .10). Recent receipt of seasonal influenza vaccination and older age were associated with attenuated response. No vaccine-related serious adverse events occurred. Solicited postvaccination symptoms were generally mild with more local symptoms seen in participants who received the adjuvant.CONCLUSIONS AND RELEVANCE Point-of-use mixing and administration of 2 doses of H7N9 vaccine at the lowest tested antigen dose with MF59 adjuvant produced seroconversion in 59% of participants. Although these findings indicate potential value in this approach, the study is limited by the absence of antibody data beyond 42 days and the absence of clinical outcomes.

Characterization of gene methylation in human papillomavirus associated-head and neck squamous cell carcinoma

“…Our study revealed that methylation frequency of APC is markedly increased in primary tumors, which was consistent with previous reports in rectal (Leong et al, 2011), breast (Mulligan et al, 2014), colorectal, and gastrointestinal cancers (Esteller et al, 2001). Furthermore, APC displayed higher degrees of methylation in patients with lymph node metastasis or higher TNM stages, which was also in accordance with results from breast cancer studies (Mulligan et al, 2014).…”

Vaccine-elicited antibody that neutralizes H5N1 influenza and variants binds the receptor site and polymorphic sites

“…Subsequent infection or immunization with a variant strain would likely be an effective route to generate broadly reactive anti-H5 antibodies. Such strategies are known to be effective within influenza subtypes (25,48,49). Our structural understanding of H5.3 supports the hypothesis that repeated challenge through immunization or infection is an effective strategy to enhance universal binding determinants, such as a CDRH3 loop that effectively binds conserved features of the RBS, similar to the natural receptor, while minimizing strainspecific interactions.…”

Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose

“…nanoparticle | vaccine platform | replicon | viruses | parasites T oday, there are a range of vaccine technologies used clinically, with varied use of inactivated pathogens, molecular antigens, adjuvants, delivery technologies, administration routes, and dosing regimes (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13). Although existing vaccine systems have had a huge impact on prevention of infectious disease, challenges remain.…”